相关实验视频

Updated: Jan 13, 2026

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

在早期患有雌激素受体低表达性乳腺癌的预后和内分泌治疗疗效

Sihua Liu¹, Beidi Du¹, Mengmeng Zhang¹

¹Breast Disease Center, The First Affiliated Hospital, Sun Yat-Sen University, No.58, Zhong Shan Er Lu, Guangzhou, 510080, China.

Breast cancer research and treatment

|January 6, 2026

概括

低雌激素受体 (ER-low) 乳腺癌的预后因HER2状态而异. 内分泌疗法有利于低ER,HER2-阴性患者通过减少复发,但不是低ER,HER2-阳性患者.

科学领域:

在瘤学瘤学.
乳腺癌研究研究乳腺癌研究
内分泌学在内分泌学.

背景情况:

低雌激素受体 (ER) 乳腺癌代表了一个独特的亚型,对其临床行为和治疗反应的理解正在不断发展.
准确的预后和确定低ER乳腺癌的有效疗法对于个性化治疗策略至关重要.

研究的目的:

研究雌激素受体 (ER) 低表达在早期乳腺癌的预后影响.
评估内分泌疗法 (ET) 在患有低ER乳腺癌的患者的疗效,按人体表皮生长因子受体2 (HER2) 状态分层.

主要方法:

对2951名在2010-2020年期间被诊断为乳腺癌早期阶段的患者进行了回顾性队列研究.
在ER低,ER高和ER负组中比较临床病理特征,生存结果 (无乳腺癌生存率,局部区域复发,远程转移) 和ET影响.
基于HER2状态 (阳性或阴性) 的分析分层.

主要成果:

与高ER患者相比,低ER患者,特别是HER2阴性亚组患者的乳腺癌无存活率明显降低,局部区域复发风险更高.
在HER2阴性亚组中,低ER和ER阴性患者之间没有观察到显著的预后差异.
内分泌疗法显著改善了无乳腺癌存活率,并降低了HER2-负组低ER患者的复发/转移风险.
在HER2阳性小组中,低ER状态没有显著影响预后,ET也没有改善生存结果.

结论:

HER2阴性/低ER乳腺癌与三阴性乳腺癌具有临床特征,受益于内分泌治疗以减少复发和转移.
对于HER2阳性乳腺癌患者来说,低ER表达似乎不是预后因素或内分泌治疗益处的明确指标.

关键词:

乳腺癌是什么? 乳腺癌是什么?在低ER-低ER.内分泌疗法是一种内分泌疗法.预测预后预测预测

更多相关视频

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Published on: February 21, 2014

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...